3 Brand-Name, Ultra-High-Yield Dividend Stocks Patient Investors Can Confidently Buy With $300 Right Now
A trio of high-octane income stocks -- sporting an average yield of 6.65% -- can fatten investors' pocketbooks in 2025 (and ...
The Westside Gazette1d
America for Sale: Pam Bondi’s Role in Trump’s Corrupt Machine
Pam Bondi’s office had the opportunity to hold Trump University accountable for its fraudulent practices, which scammed ...
Pfizer: 3 Key Risks That Warrant A Sell
Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...
Health companies return $2.6 trillion to shareholders over time amid rising medical costs
Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...
Business Wire2d
Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform
Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...
Pfizer: Challenges Loom Amid Overvaluation
Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...
STAT7d
AstraZeneca offers some reassurance on China challenges
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...
Contract Pharma8d
Pfizer 4Q Results
4Q Earnings: $410 million (loss of $3.4 billion 4Q24) ...
Hosted on MSN8d
Pfizer earnings exceed estimates
NEW YORK — Pfizer reported better-than-expected quarterly profits on Tuesday behind cost cuts and growth in some non-Covid-related products including the blood clot drug Eliquis. Other pharmaceuticals ...